Parkinson disease and impulse control disorders: A review of clinical features, pathophysiology and management

Postgraduate Medical Journal

Volumn 85, Issue 1009, 2009, Pages 590-596

  Wu, K ^a   Politis, M ^a   Piccini, P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; QUETIAPINE;

ALCOHOLISM; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COMORBIDITY; COMPULSIVE SHOPPING; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE DYSREGULATION SYNDROME; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG OVERDOSE; DYSKINESIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; NERVE CELL; ONSET AGE; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERSONALITY; PHAGOMANIA; PHENOMENOLOGY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; RESTLESS LEGS SYNDROME; REVIEW; SENSITIZATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYNDROME;

DEEP BRAIN STIMULATION; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DOPAMINE AGENTS; DOPAMINE AGONISTS; HUMANS; IMPULSE CONTROL DISORDERS; PARKINSON DISEASE; PATIENT EDUCATION AS TOPIC;

EID: 73249142830     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.075820     Document Type: Review

References (79)

1. Pontone G, Williams R, Spear Bassett S, et al. Clinical features associated with impulse control disease in Parkinson's Disease. Neurology 2006;67:1258-61.
2. Weintraub D, Siderowf AD, Potenza MN, et al. Dopamine agonist use is associated with impulse control disorders in PD. Arch Neurol 2006;63:969-73.
3. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviours in PD. Neurology 2006;67:1254-7.
4. Lawrence AD, Evans AH, Less AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward system gone awry? Lancet Neurol 2003;2:595-604.
5. Evans AH, Lawrence AD, Potts J, et al. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson's disease. Neurology 2005;65:1570-4.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders - text revision. 4th edn. Washington DC: American Psychiatric Association, 2000.
7. Brewer J, Potenza M. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008;75:63-75.
8. British Gambling Prevalence Survey. http://www.gamblingcommission. gov.uk/Client/detail.asp?Contentid=311 (accessed 20 Jul 2009).
9. Shaffer HJ, Hall MN, Vanderbilt J. Estimating the prevalence of disordered gambling behaviour in the United States and Canada: a research synthesis. Am J Public Health 1999;89:1369-76.
10. Koran LM, et al. Estimated prevalence of compulsive buying in the United States. Am J Psychiatry 2006;163:1806-12.
11. Chambers RA, Potenza MN. Neurodevelopment, impulsivity and adolescent gambling. J Gambl Stud 2003;19:53-84.
12. Wilber MK, Potenza MN. Adolescent gambling: research and clinical implications. Psychiatry 2006;3:40-8.
13. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006;21:2206- 8.
14. McElroy SL, et al. Compulsive buying: a report of 20 cases. J Clin Psychiatry 2004;55:242-8.
15. Slutske WS, et al. A twin study of the association between pathological gambling and antisocial personality disorder. J Abnorm Psychol 2001;110:297-308.
16. Cunningham-Williams RM, Grucza RA, Cottler LB, et al. Prevalence and predictors of pathological gambling: results for the St. Louis personality, health and lifestyle (SLPHL) study. J Psychiatr Res 2005;39:377-90.
17. Potenza MN, et al. Shared genetic contributions to pathological gambling and major depression in men. Arch Gen Psychiatry 2005;62:1015-21.
18. Ondo WG, Lai D. Predictors of impulsivity and reward seeking behaviour with dopamine agonists. Parkinsonism Relat Disord 2008;14:28-32.
19. Pessiglione M, Seymour B, Flandin G, et al. Dopamine dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006;442:1042-5.
20. Oakley-Browne MA, Adams P, Mobberley PM. Interventions for pathological gambling. Cochrane Database Syst Rev 2000;(2):CD001521.
21. Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry 2009;22:69-74.
22. Potenza MN. Impulse control disorders and co-occurring disorders: dual diagnosis considerations. J Dual Diagn 2007;3:47-57.
23. Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drugrelated pathological gambling in Parkinson's disease. Arch Neurol 2007;64:212-16.
24. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathological gambling in patients with Parkinson's disease: a behavioural manifestation of pharmacologic treatment? Mov Disord 2000;15:869-72.
25. Gschwandtner U, et al. Pathological gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24:170-2.
26. Dodd ML, et al. Pathological gambling caused by drugs used to treat Parkinson's disease. Arch Neurol 2005;62:1377-81.
27. Wingo TS, Evatt M, Scott N, et al. Impulse control disorders arising in 3 patients treated with rotigotine. Clin Neuropharmacol 2009:32:59-62.
28. Evans, et al. Punding in PD: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
29. Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathological gambling and medication association in PD. Neurology 2006;66:1750-2.
30. Lu C, Bharmal A, Suchowersky O. Gambling and PD. Arch Neurol 2006;63:298.
31. Petry NM, Stinson FS, Grant BF. Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic survey on Alcohol and Related Conditions. J Clin Psychiatry 2005;66:564-73.
32. Giovannoni G, O'Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with PD on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-8.
33. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009;23:157-70.
34. Wise RA, Bozareth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-92.
35. Miyasaki JM, Al Hassan K, Lang AE, et al. Punding prevalence in Parkinson's disease. Mov Disord 2007;22:1179-81.
36. Friedman J. Punding on levodopa. Biol Psychiatry 1994;36:350-1.
37. Fernandez H, Friedman J. Punding on levodopa. Mov Disord 1999;14:836-8.
38. O'Sullivan SS, Evans AH, Lees AJ. Punding in Parkinson's disease. Pract Neurol 2007;7:397-9.
39. Fasano A, Barra A, Nicosia P, et al. Cocaine addiction: from habits to stereotypicalrepetitive behaviours and punding. Drug Alcohol Depend 2008;96:178-82.
40. Stamey W, Jankovic J. Impulse control disorders and pathological gambling in patients with Parkinson's disease. Neurologist 2008;14:89-99.
41. Lobo DSS, Kennedy JL. The genetics of gambling and behavioural addictions. CNS Spectr 2006;11:931-9.
42. Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemol Ment Health 2005;1:21.
43. Frankle WG, Lombardo I, Mew As, et al. Brain serotonin transporter distribution in subjects with impulse aggressivity: a positron emission study with 11C McN 5652. Am J Psychiatry 2005;162:915-23.
44. Evans AH, Butzkueven H. Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Mov Disord 2007;22:590-1.
45. Tippmann-Peikert M, Park JG, Boeve BF, et al. Pathological gambling in patients with restless leg syndrome treated with dopaminergic agonists. Neurology 2007;68:301-3.
46. Quickfall J, Schowersky O. Pathological gambling associated with dopamine agonist use in restless leg syndrome. Parkinsonism Relat Disord 2007;13:533-6.
47. Driver-Dunckley ED, Noble BN, Hentz JG, et al. Gambling and increased sexual desire with dopaminergic medications in restless leg syndrome. Clin Neuropharmacol 2007;30:249-55.
48. Benninger RJ, Banasikowski TJ. Dopaminergic mechanism of reward-related incentive learning: focus on the dopamine D3 receptor. Neurotox Res 2008;14:57-70.
49. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioural sensitisation to levodopa. Proc Natl Acad Sci USA 1997;94:3363-7.
50. Singh A, Kandimala G, Dewey R, et al. Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonist. J Clin Neurosci 2007;14:1178-81.
51. Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Mov Disord 2000;15:1014-16.
52. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8:1481-9.
53. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003;54:25-53.
54. Robinson TE, Berridge KC. The neural basis of drug craving: an incentivesensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247-91.
55. Robinson TE, Berridge KC. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000;95(Suppl 2):91-117.
56. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8:147-8.
57. Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003;160:1990-4.
58. Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003;60:828-36.
59. Hollander E, Buchsbaum MS, Haznedar MM. FDG-PET study in pathological gamblers. 1. Lithium increases orbitofrontal, dorsolateral and cingulated metabolism. Neuropsychobiology 2008;58:37-47.
60. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict train impulsivity and cocaine reinforcement. Science 2007;315:1267-70.
61. Cilia R, Siri C, Marotta G, et al. Functional abnormalities underlying pathological gambling in Parkinson's Disease. Arch Neurol 2008;65:1604-11.
62. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitised ventral striatal dopamine transmission. 2006;59:852-8.
63. Toates F. The interaction of cognitive and stimulus-response processes in the control of behaviour. Neurosci Biobehav Rev 1998;22:59-83.
64. Ikemoto S, Panksepp J. The role of nucleus accumbens dopamine in motivated behaviour: a unifying interpretation with special references to reward-seeking. Brain Res Brain Res Rev 1999;31:6-41.
65. Kunig G, Leenders KL, Martin-Solch C, et al. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport 2000;11:2681-7.
66. Tearse G. Parkinson's drugs 'made me gambler, thief and gay sex friend'. The Observer 9 December 2007.
67. BNF. British National Formulary March 2009;57:266-7.
68. Carroll KM, Onken LS. Behavioural therapies for drug abuse. Am J Psychiatry 2005;162:1452-60.
69. Dowling N, Smith D, Thomas T. Treatment of female pathological gambling: the efficacy of a cognitive-behavioural approach. J Gambl Stud 2006;22:355-72.
70. Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/ placebo crossover trial in pathological gambling. Biol Psychiatry 2000;47:813-17.
71. Kim SW, Grant JE, Adson DE, et al. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002;63:501-7.
72. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychol 2008;69:783-9.
73. Huerto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002;72:701-7.
74. Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow-up. J Neurol Neurosurg Psychiatry 2005;76:1640-4.
75. Bandini F, Promavera A, Pizzorno M, et al. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonian Relat Disord 2007;13:369-71.
76. Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21:1941-6.
77. Mallet L, Mesnage V, Houeto JL, et al. Compulsion, Parkinson's disease and stimulation. Lancet 2002;360:1302-4.
78. Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006;66:1830-6.
79. Smeding HM, Goudriaan AE, Foncke EM, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007;78:517-19.